Treating Castration-Resistant Prostate Cancer

Opinion
Video

Medical oncologists provide clinical insights on treatment paradigms for patients with castration-resistant prostate cancer, highlighting how next-generation sequencing informs treatment decisions.

Recent Videos
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Related Content
Phase 2 data support further evaluation of nivolumab plus standard radiotherapy in patients with Gleason grade 5 prostate cancer.

Nivolumab/RT Improves Biochemical Recurrence Outcomes in Prostate Cancer

Russ Conroy
October 4th 2024
Article

Phase 2 data support further evaluation of nivolumab plus standard radiotherapy in patients with Gleason grade 5 prostate cancer.

AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.

Leveraging Artificial Intelligence Evolutions in Prostate Cancer Care

James B. Yu, MD, MHS, FASTRO;Julian C. Hong, MD, MS
July 1st 2024
Podcast

AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.

Data show no differences in bowel function between treatment arms based on factors including age, disease risk, and fractionation schedule.

IMRT Yields Similar QOL Vs Proton Therapy in Localized Prostate Cancer

Russ Conroy
September 30th 2024
Article

Data show no differences in bowel function between treatment arms based on factors including age, disease risk, and fractionation schedule.

Oncology Peer Review On-The-Go: Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIs

Oncology Peer Review On-The-Go: Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIs

Judd W. Moul, MD;Kostantinos E. Morris, BS
May 30th 2022
Podcast

Judd W. Moul, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on the treatment of a patients with evidence of prostate cancer despite multiple negative prognostic tests.

rPFS/OS Benefit in Radium-223 Plus Enzalutamide in mCRPC

rPFS/OS Benefit in Radium-223 Plus Enzalutamide in mCRPC

Megan Hollasch
September 14th 2024
Article

Significant survival benefits were observed with Radium-223 plus enzalutamide in patients with metastatic castration-resistant prostate cancer.

Recent FDA approvals of the companion diagnostics may help improve personalized treatment decision-making for patients with prostate cancer.

FDA Approves FoundationOne Tests for Olaparib Combo in BRCA-Mutated mCRPC

Harrison Widelitz
September 5th 2024
Article

Recent FDA approval of the companion diagnostics may help improve personalized treatment decision-making for patients with prostate cancer.